[go: up one dir, main page]

TWI732762B - 口服持續釋放調配物 - Google Patents

口服持續釋放調配物 Download PDF

Info

Publication number
TWI732762B
TWI732762B TW105116842A TW105116842A TWI732762B TW I732762 B TWI732762 B TW I732762B TW 105116842 A TW105116842 A TW 105116842A TW 105116842 A TW105116842 A TW 105116842A TW I732762 B TWI732762 B TW I732762B
Authority
TW
Taiwan
Prior art keywords
weight
parts
cilostazol
release formulation
sustained
Prior art date
Application number
TW105116842A
Other languages
English (en)
Chinese (zh)
Other versions
TW201707688A (zh
Inventor
崔然雄
閔炳九
趙相珉
張宰常
崔志賢
Original Assignee
南韓商韓國聯合製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57441116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI732762(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 南韓商韓國聯合製藥股份有限公司 filed Critical 南韓商韓國聯合製藥股份有限公司
Publication of TW201707688A publication Critical patent/TW201707688A/zh
Application granted granted Critical
Publication of TWI732762B publication Critical patent/TWI732762B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
TW105116842A 2015-05-29 2016-05-27 口服持續釋放調配物 TWI732762B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150076256A KR101748215B1 (ko) 2015-05-29 2015-05-29 경구용 서방성 제제
KR10-2015-0076256 2015-05-29

Publications (2)

Publication Number Publication Date
TW201707688A TW201707688A (zh) 2017-03-01
TWI732762B true TWI732762B (zh) 2021-07-11

Family

ID=57441116

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105116842A TWI732762B (zh) 2015-05-29 2016-05-27 口服持續釋放調配物

Country Status (6)

Country Link
KR (1) KR101748215B1 (es)
AR (2) AR104811A1 (es)
PH (1) PH12015000296B1 (es)
RU (1) RU2696870C2 (es)
TW (1) TWI732762B (es)
WO (1) WO2016195154A1 (es)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548543A (zh) * 2009-09-23 2012-07-04 韩国联合制药株式会社 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
KR20070024254A (ko) * 2005-08-26 2007-03-02 한국오츠카제약 주식회사 실로스타졸 함유 서방정
KR101068475B1 (ko) * 2009-12-29 2011-09-28 환인제약 주식회사 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법
KR20130106456A (ko) * 2011-04-29 2013-09-30 한국유나이티드제약 주식회사 약물 방출제어용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102548543A (zh) * 2009-09-23 2012-07-04 韩国联合制药株式会社 具有改进的溶出率和最小的副作用的缓释的西洛他唑片剂

Also Published As

Publication number Publication date
TW201707688A (zh) 2017-03-01
AR134066A2 (es) 2025-11-26
AR104811A1 (es) 2017-08-16
WO2016195154A1 (ko) 2016-12-08
KR101748215B1 (ko) 2017-06-20
PH12015000296A1 (en) 2017-03-13
RU2017140447A3 (es) 2019-07-17
KR20160141253A (ko) 2016-12-08
RU2017140447A (ru) 2019-07-02
RU2696870C2 (ru) 2019-08-07
PH12015000296B1 (en) 2017-03-13

Similar Documents

Publication Publication Date Title
JP5627455B2 (ja) 速崩性錠剤製造のための医薬製剤
CN101636152B (zh) 含有西洛他唑的控释制剂及其制备方法
JP5750847B2 (ja) アトルバスタチン経口投与用粒子状医薬組成物
CN101534792A (zh) 包含氧可酮的粒剂和口腔崩解片剂
WO2015132708A1 (en) Pharmaceutical composition of roflumilast
JP5534004B2 (ja) 口腔内崩壊錠
WO2020249001A1 (zh) 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
CN101631533B (zh) 含有西洛他唑的控释制剂及其制备方法
WO2019151405A1 (ja) 錠剤及びその製造方法
JP6680297B2 (ja) 経口投与用医薬組成物
JP2020518611A (ja) 水溶解度及びバイオアベイラビリティが改善された組成物
AU2016259762A1 (en) Vortioxetine pyroglutamate
CN112449601A (zh) 含纳呋拉啡口腔崩解片
CN108012526A (zh) 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法
CN101854921B (zh) 用于口服施用ppi的药物制剂
WO2016012898A1 (en) Oral pharmaceutical composition of lurasidone
WO2021153525A1 (ja) エソメプラゾール経口製剤およびその製造方法
JP7585043B2 (ja) レナリドミドを含む医薬組成物
TWI732762B (zh) 口服持續釋放調配物
TWI586379B (zh) 一種製作難溶藥物固體劑型的方法
CN108096251B (zh) 一种吉非替尼药物组合物及其制备方法
WO2017009754A1 (en) Orally administrable film dosage form containing fingolimod
WO2014157603A1 (ja) 経口投与用医薬組成物
JP7581712B2 (ja) アビラテロン酢酸エステル含有製剤
KR101428149B1 (ko) 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법